CB-183,315 — Competitive Intelligence Brief

CB-183,315 (CB-183,315) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bacterial protein synthesis inhibitor. Area: Infectious Disease.

phase 3 Bacterial protein synthesis inhibitor Bacterial ribosome Infectious Disease Small molecule

Target snapshot

CB-183,315 (CB-183,315) — Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). CB-183,315 is a selective inhibitor of bacterial protein synthesis that targets gram-positive pathogens by binding to the bacterial ribosome.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CB-183,315 TARGET	CB-183,315	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 3	Bacterial protein synthesis inhibitor	Bacterial ribosome
Duac® fixed dose combination gel	Duac® fixed dose combination gel	GlaxoSmithKline	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Interferon beta 1a, oral doxycycline	Interferon beta 1a, oral doxycycline	Louisiana State University Health Sciences Center Shreveport	marketed	Cytokine + tetracycline antibiotic combination	Interferon-beta receptor (IFNBR); doxycycline targets bacterial ribosomes and matrix metalloproteinases
Duac® Gel / Differin® Gel	Duac® Gel / Differin® Gel	Stiefel, a GSK Company	marketed	Topical antibiotic/antimicrobial combination (Duac®); Topical retinoid (Differin®)	Bacterial ribosome (clindamycin); Retinoic acid receptor (adapalene); Reactive oxygen species generation (benzoyl peroxide)
Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	American University of Beirut Medical Center	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (rabeprazole); bacterial ribosome and DNA (metronidazole, clarithromycin); bacterial cell wall (amoxicillin)
Lansoprazole/Amoxicillin/Clarithromycin	Lansoprazole/Amoxicillin/Clarithromycin	HK inno.N Corporation	marketed	Proton pump inhibitor + antibiotic combination	H+ ATPase (lansoprazole); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)
Vonoprazan+amoxicillin+clarithromycin 14 days	Vonoprazan+amoxicillin+clarithromycin 14 days	Xijing Hospital of Digestive Diseases	marketed	Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) + macrolide antibiotic (clarithromycin)	H+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bacterial protein synthesis inhibitor class)

1. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
2. Hoffmann-La Roche · 1 drug in this class